334 related articles for article (PubMed ID: 10431020)
1. Use of antilymphocyte induction therapy in liver transplantation: A European perspective.
Langrehr JM; Neuhaus PJ
Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S71-84. PubMed ID: 10431020
[No Abstract] [Full Text] [Related]
2. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
McVicar JP; Kowdley KV; Emond MJ; Barr D; Marsh CL; Carithers RL; Perkins JD
Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724
[TBL] [Abstract][Full Text] [Related]
3. Use of antilymphocyte induction therapy in liver transplantation.
Wall WJ
Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S64-70. PubMed ID: 10431019
[TBL] [Abstract][Full Text] [Related]
4. Effect of HLA matching and T- and B-cell crossmatch on acute rejection and graft survival following liver transplantation.
Chen M; Wade J; Levy GA; Greig PD
Transplant Proc; 1994 Oct; 26(5):2695-6. PubMed ID: 7940844
[No Abstract] [Full Text] [Related]
5. Immunosuppression is not related to the response to steroids in acute liver rejection.
Bercedo J; Jiménez C; Moreno E; García MA; Palomo JC; Loinaz C; Marcello M; Moreno C; Chamorro A; Manzanera M
Transplant Proc; 1995 Aug; 27(4):2328-9. PubMed ID: 7652830
[No Abstract] [Full Text] [Related]
6. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
Lange D; Bechstein WO; Blumhardt G; Lemmens P; Schattenfroh N; Neuhaus P
Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207
[No Abstract] [Full Text] [Related]
7. Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation.
Klupp J; Bechstein WO; Pratschke J; Tullius SG; Gebhard A; Lobeck H; Langrehr JM; Neuhaus R; Neuhaus P
Transplant Proc; 1998 Jun; 30(4):1443-4. PubMed ID: 9636585
[No Abstract] [Full Text] [Related]
8. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation.
Bruce DS; Newell KA; Woodle ES; Millis JM; Piper JB; Huss E; Thistlethwaite JR
Transplant Proc; 1996 Aug; 28(4):2136-7. PubMed ID: 8769180
[No Abstract] [Full Text] [Related]
9. Induction therapy: why, when, and which agent?
Krischock L; Marks SD
Pediatr Transplant; 2010 May; 14(3):298-313. PubMed ID: 20345609
[TBL] [Abstract][Full Text] [Related]
10. Hepatic allograft rejection under quadruple immunosuppressive regimen with cyclosporine A in liver transplantation: incidence of viral and fungal infection.
Fabregat J; Fradera R; Figueras J; Rafecas A; Torras J; Martinez LaCasa J; Baliellas C; Casais L; Jaurrieta E
Transplant Proc; 1994 Oct; 26(5):2697-9. PubMed ID: 7940845
[No Abstract] [Full Text] [Related]
11. Accelerated liver allograft rejection during prophylactic immunosuppression with OKT3.
Sasaki AW; Lee RG; Porayko MK; Benner KG; Hennell KR; Wheeler LJ; Pinson CW
Transplantation; 1993 Jan; 55(1):216-9. PubMed ID: 8420054
[No Abstract] [Full Text] [Related]
12. Optimal immunosuppressive clinical regimen in liver transplantation.
Farges O; Samuel D; Bismuth H
Transplant Proc; 1994 Oct; 26(5):2676-8. PubMed ID: 7940838
[No Abstract] [Full Text] [Related]
13. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?
Higgins R; Kirklin JK; Brown RN; Rayburn BK; Wagoner L; Oren R; Miller L; Flattery M; Bourge RC;
J Heart Lung Transplant; 2005 Apr; 24(4):392-400. PubMed ID: 15797738
[TBL] [Abstract][Full Text] [Related]
14. Antithymocyte globulin or interleukin 2 receptor antibody for immunosuppressive induction therapy after orthotopic liver transplantation: a follow-up study.
Keck H; Langrehr JM; Knoop M; Lohmann R; Neuhaus P
Transplant Proc; 1993 Aug; 25(4):2701. PubMed ID: 8356721
[No Abstract] [Full Text] [Related]
15. IL-2 receptor antibody induction increases the risk for chronic rejection after liver transplantation.
Langrehr JM; Lohmann R; Guckelberger O; Müller AR; Raakow R; Nüssler NC; Klupp J; Pfitzmann R; Jonas S; Settmacher U; Steinmüller T; Neuhaus P
Transplant Proc; 2001; 33(1-2):1433-4. PubMed ID: 11267360
[No Abstract] [Full Text] [Related]
16. Posttransplant lymphoproliferative disorders in liver recipients treated with OKT3 or ALG induction immunosuppression.
McAlister V; Grant D; Roy A; Yilmaz Z; Ghent C; Wall W
Transplant Proc; 1993 Feb; 25(1 Pt 2):1400-1. PubMed ID: 8442154
[No Abstract] [Full Text] [Related]
17. Interleukin-2 receptor antibody versus antithymocyte globulin as part of quadruple induction therapy after orthotopic liver transplantation: a randomized study.
Langrehr JM; Guckelberger O; Nüssler N; Radtke A; Lemmens HP; Jonas S; Lohmann R; Tullius S; Steinmüller T; Raakow R; Neumann U; Knoop M; Bechstein WO; Neuhaus P
Transplant Proc; 1996 Dec; 28(6):3204. PubMed ID: 8962241
[No Abstract] [Full Text] [Related]
18. [Implications of the immunologic response to the graft in the design of immunosuppressive treatment for liver transplantation].
de la Mata M; Barrera P; Montero JL; Fraga E; Briceño J; Pozo JC; Solórzano G
Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():52-6. PubMed ID: 15195535
[No Abstract] [Full Text] [Related]
19. Strategies of immunosuppression in cardiac transplantation.
Renlund DG; O'Connell JB; Bristow MR
Semin Thorac Cardiovasc Surg; 1990 Apr; 2(2):181-8. PubMed ID: 2127901
[TBL] [Abstract][Full Text] [Related]
20. Value of monoclonal antibody OKT3 in solid organ transplantation: a meta-analysis.
Carrier M; Jenicek M; Pelletier LC
Transplant Proc; 1992 Dec; 24(6):2586-91. PubMed ID: 1465874
[No Abstract] [Full Text] [Related]
[Next] [New Search]
